Would it different from Vioxx? The challenge of the COX-2 inhibitor, Arcoxia, will begin

MSD has challenged the COX-2 inhibitor market again. However, it is analyzed that the expected result for the new challenge would not be different from the old one.

The Ministry of Food and Drug Safety, on the 24^th, gave the domestic sale approval of the non-steroidal anti-inflammatory drugs-type selective COX-2 inhibitor ‘Arcoxia (generic name: etoricoxib)’.

Unlike other multinational pharma...